Routine COO departure with no financial or operational read-through. The reorganization is already underway with an Interim CEO in place. No trading action warranted.
Price Chart
Executive Summary
Anavex Life Sciences Corp. disclosed the departure of COO Felix Lauscher on May 11, 2026, as part of a broader reorganization following the appointment of Dr. Terrie Kellmeyer as Interim CEO. Lauscher had held the role for only about two months since March 1, 2026. The filing is a routine officer departure with no material financial impact.
Key Facts
- COO Felix Lauscher departed on May 11, 2026, after only ~2.5 months in the role (since March 1, 2026).
- Departure described as part of a broader reorganization following appointment of Interim CEO Dr. Terrie Kellmeyer.
- Lauscher's annual base salary was $264,000; he received a prorated amount for his service period.
- He was granted 50,000 stock options; 45,833 were forfeited immediately, and 4,167 vested on March 31, 2026, exercisable at $4.69/share until August 9, 2026.
- He was offered two weeks' additional compensation at his base salary in exchange for a general release.
Financial Impact
Immaterial — total severance cost is approximately $10,154 (two weeks at $264,000 annual salary) plus the value of 4,167 vested options.
Risk Factors
- Further C-suite turnover could signal deeper organizational instability, but this single departure is not a red flag.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001731122-26-000744 |
| Document: 0001731122-26-000744-index-headers.html | 0001731122-26-000744 |
| Document: 0001731122-26-000744-index.html | 0001731122-26-000744 |
| Document: 0001731122-26-000744.txt | 0001731122-26-000744 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $1.36 | awaiting T+60 | — | $1.26 (−7.28%) |
Oct 20, 2026 6d ago | Press Release | $1.36 | awaiting T+60 | — | $1.26 (−7.28%) |
Oct 15, 2026 11d ago | 8-K | $1.31 | awaiting T+60 | — | $1.26 (−3.74%) |
Oct 15, 2026 11d ago | Press Release | $1.31 | awaiting T+60 | — | $1.26 (−3.74%) |
Sep 28, 2026 28d ago | 8-K | $2.36 | awaiting T+60 | — | $1.26 (−46.57%) |
Sep 17, 2026 5w ago | DFAN14A | $2.41 | awaiting T+60 | — | $1.26 (−47.68%) |
Sep 15, 2026 6w ago | DFAN14A | $2.44 | awaiting T+60 | — | $1.26 (−48.32%) |
Sep 14, 2026 6w ago | DEFA14A | $2.60 | awaiting T+60 | — | $1.26 (−51.50%) |
Sep 4, 2026 7w ago | DEFA14A | $2.85 | awaiting T+60 | — | $1.26 (−55.75%) |
Sep 3, 2026 7w ago | DFAN14A | $2.86 | awaiting T+60 | — | $1.26 (−55.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers